Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

200883 citationsJournal Article

Authors

Brigitte Autran · Pitié-Salpêtrière Hospital

Robert L. Murphy · Assistance Publique – Hôpitaux de Paris

Dominique Costagliola · Assistance Publique – Hôpitaux de Paris

Roland Tubiana · Sorbonne Université

Bonaventura Clotet · IrsiCaixa

José M. Gatell · Hospital Clínic de Barcelona

Schlomo Staszewski

Abstract

Significant immunogenicity was induced by vCP1452; however, this strategy was independently associated with a shorter time to resume therapy and higher viral rebound.

Topics & Keywords

HIV Research and Treatment Herpesvirus Infections and Treatments HIV/AIDS Research and Interventions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: AIDS

Volume 22, Issue 11, pp. 1313-1322

DOI: 10.1097/qad.0b013e3282fdce94

Field-Weighted Citation Impact: 2.74